Category Archives: Patently BIOtech

Corporate-Sponsored University Research Valuable for Further Innovation

SBIR Reauthorization Moves Forward

New research published in Nature, Technology Transfer: Industry-funded academic inventions boost innovation, provides data undermining “assumptions that corporate-funded academic research is less accessible and useful to others.” After reviewing empirical evidence covering 20 years of inventions in the University of California system the authors find that: “Corporate-sponsored research is surprisingly valuable for further innovation. Data collected over 20 years at nine campuses and three national laboratories administered by the University of California show that corporate-sponsored Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Gene Patent Questions Remain: USPTO Issues Examiner Guidelines

Supreme Court

The new Patent Office guidance, issued March 4, extends the Supreme Court’s legal logic into areas that were neither mentioned nor decided in the Myriad case itself. Myriad went to the Supreme Court exclusively on the question whether human genes are patentable. And human genetic diagnostic testing was the only context in which the Supreme Court thought about this question. The Supreme Court also acknowledged that it is not a scientific expert, and perhaps recognized Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

Special 301: BIO Highlights Challenges in India

cells115x76

BIO recently testified before the U.S. government on the intellectual property challenges our members face in various markets around the world. Among other matters, BIO recommended that the U.S. government designate India as a Priority Foreign Country, a designation that would lead to the consideration of trade sanctions for treaty violations. Specifically, BIO testified: “In the healthcare space, only a few dozen innovative and patent protected medicines are on the market in India. Yet, in Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Report Shows World’s Weakest IP Environments

admin-ajax

There is clear link between a country’s rate of economic development and the strength of its intellectual property laws. This is particularly true in knowledge-intensive sectors such as biopharmaceuticals. The good news is that some mature and emerging economies are making growing use of patent systems to facilitate biotechnology research and commercialization. The bad news is that a number of countries, including India, China, Brazil and Canada, have established bureaucratic and burdensome hurdles to patentability. Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

TPP and IP: The Economic Benefits of a Pacific Trade Agreement

scientists115x76

Ndp Analytics recently published a study on the economic benefits of intellectual property rights (IP) in the Trans-Pacific Partnership. They find that 2/3’s of the “economic benefits for the U.S. economy and the 11 partner countries would come from IP-intensive manufacturing industries.” They conclude that “the stronger the protection of IP rights under the TPP, the greater the value of trade leading to greater economic growth, additional jobs created, higher incomes, and development across countries.” Here Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,